2,011 Shares in Eli Lilly and Company (NYSE:LLY) Bought by Keynote Financial Services LLC

Keynote Financial Services LLC acquired a new stake in Eli Lilly and Company (NYSE:LLY) during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund acquired 2,011 shares of the company’s stock, valued at approximately $1,564,000. Eli Lilly and Company accounts for approximately 1.3% of Keynote Financial Services LLC’s holdings, making the stock its 17th biggest holding.

Other hedge funds also recently made changes to their positions in the company. Lipe & Dalton acquired a new stake in Eli Lilly and Company in the fourth quarter valued at about $26,000. Core Wealth Advisors Inc. lifted its holdings in shares of Eli Lilly and Company by 188.2% in the 4th quarter. Core Wealth Advisors Inc. now owns 49 shares of the company’s stock valued at $29,000 after buying an additional 32 shares during the period. Activest Wealth Management purchased a new stake in shares of Eli Lilly and Company in the first quarter valued at approximately $39,000. Tidemark LLC acquired a new position in Eli Lilly and Company during the fourth quarter worth $29,000. Finally, Redmont Wealth Advisors LLC purchased a new position in Eli Lilly and Company in the first quarter worth $40,000. Institutional investors and hedge funds own 82.53% of the company’s stock.

Eli Lilly and Company Trading Down 3.4 %

Shares of NYSE:LLY traded down $27.98 during midday trading on Friday, reaching $804.46. The company’s stock had a trading volume of 3,515,933 shares, compared to its average volume of 3,316,491. The firm has a market cap of $764.57 billion, a price-to-earnings ratio of 118.48, a price-to-earnings-growth ratio of 1.81 and a beta of 0.41. The business has a 50 day moving average price of $870.80 and a 200 day moving average price of $788.92. Eli Lilly and Company has a 1 year low of $446.89 and a 1 year high of $966.10. The company has a quick ratio of 1.03, a current ratio of 1.35 and a debt-to-equity ratio of 1.90.

Eli Lilly and Company (NYSE:LLY) last posted its quarterly earnings results on Monday, May 6th. The company reported $2.58 EPS for the quarter, beating the consensus estimate of $2.53 by $0.05. The company had revenue of $8.77 billion during the quarter, compared to analysts’ expectations of $8.94 billion. Eli Lilly and Company had a return on equity of 56.98% and a net margin of 17.08%. The firm’s revenue was up 26.0% on a year-over-year basis. During the same quarter in the previous year, the business earned $1.62 EPS. Research analysts forecast that Eli Lilly and Company will post 13.79 EPS for the current year.

Eli Lilly and Company Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Tuesday, September 10th. Investors of record on Thursday, August 15th will be issued a $1.30 dividend. The ex-dividend date is Thursday, August 15th. This represents a $5.20 dividend on an annualized basis and a yield of 0.65%. Eli Lilly and Company’s payout ratio is 76.58%.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently weighed in on the stock. Argus upped their price target on shares of Eli Lilly and Company from $770.00 to $840.00 and gave the stock a “buy” rating in a research note on Tuesday, May 14th. Morgan Stanley reiterated an “overweight” rating and set a $1,023.00 price target on shares of Eli Lilly and Company in a research report on Friday, July 5th. Truist Financial restated a “buy” rating and issued a $1,000.00 price target (up previously from $892.00) on shares of Eli Lilly and Company in a report on Tuesday, June 25th. BMO Capital Markets reaffirmed an “outperform” rating and set a $1,001.00 price objective on shares of Eli Lilly and Company in a report on Wednesday, July 3rd. Finally, Bank of America reissued a “buy” rating and issued a $1,000.00 target price on shares of Eli Lilly and Company in a report on Monday, June 24th. Three research analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $858.72.

Insider Buying and Selling

In other news, major shareholder Lilly Endowment Inc sold 92,563 shares of the company’s stock in a transaction on Friday, May 24th. The stock was sold at an average price of $809.21, for a total transaction of $74,902,905.23. Following the completion of the sale, the insider now directly owns 98,556,247 shares in the company, valued at approximately $79,752,700,634.87. The transaction was disclosed in a legal filing with the SEC, which is available at this link. In other news, major shareholder Lilly Endowment Inc sold 92,563 shares of the business’s stock in a transaction dated Friday, May 24th. The stock was sold at an average price of $809.21, for a total transaction of $74,902,905.23. Following the completion of the sale, the insider now owns 98,556,247 shares in the company, valued at approximately $79,752,700,634.87. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Johna Norton sold 7,056 shares of the stock in a transaction that occurred on Monday, June 3rd. The stock was sold at an average price of $819.38, for a total transaction of $5,781,545.28. Following the sale, the executive vice president now directly owns 25,428 shares of the company’s stock, valued at approximately $20,835,194.64. The disclosure for this sale can be found here. Over the last quarter, insiders sold 1,214,704 shares of company stock valued at $1,066,841,316. Insiders own 0.13% of the company’s stock.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.